Preclinical studies and clinical trials have been processed to evaluate potential treatment options for NAFLD and NASH, including synbiotics, omega-3, CCR2/5 antagonists, FXR agonists, and so on. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.